Correlations of expression of paired-box gene family 8 and vimentin in epithelial ovarian cancer tissue with clinicopathologic features and recurrence after chemotherapy

LI Youyou; LU Dan

doi:10.7619/jcmp.20232092

Journal of Clinical Medicine in Practice > 2023 > 27(18): 1-4, 10. > DOI: 10.7619/jcmp.20232092

LI Youyou, LU Dan. Correlations of expression of paired-box gene family 8 and vimentin in epithelial ovarian cancer tissue with clinicopathologic features and recurrence after chemotherapy[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 1-4, 10. DOI: 10.7619/jcmp.20232092

Citation:

PDF (1744 KB)

Correlations of expression of paired-box gene family 8 and vimentin in epithelial ovarian cancer tissue with clinicopathologic features and recurrence after chemotherapy

LI Youyou,
LU Dan^,

Department of Obstetrics and Gynecology, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, 215000

More Information

Received Date: June 29, 2023
Revised Date: August 16, 2023
Available Online: October 08, 2023

Graphical Abstract

Abstract

Abstract

Objective
To investigate relationships of paired-box gene family 8(PAX8)and vimentin in epithelial ovarian cancer (EOC) with clinicopathologic features and recurrence after chemotherapy.
Methods
Immunohistochemistry was used to detect the expression of PAX8 and vimentin in epithelial ovarian cancer tissues of 86 cases, and the relationships of PAX8 and vimentin with clinicopathologic features and recurrence after chemotherapy.
Results
PAX8 and vimentin were highly expressed in epithelial ovarian cancer, and their positive rates were 81.4% and 55.8%. The clinical stage, proportions of lymph node metastasis and ascites in patients with PAX8 and vimentin positive expression were higher than those with negative expression (P < 0.05). In patients with recurrent epithelial ovarian cancer after chemotherapy, the number of patients with both positive expression of PAX8 and vimentin was significantly higher in patients with negative expression (P < 0.05); positive co-expression of PAX8 and vimentin was significantly correlated with recurrence after chemotherapy in patients with epithelial ovarian cancer (P < 0.001).
Conclusion
PAX8 and vimentin are highly expressed in epithelial ovarian cancer, which has a certain value in evaluating the severity and prognosis of epithelial ovarian cancer.
- epithelial ovarian cancer,
- paired-box gene family 8,
- vimentin,
- clinicopathologic features,
- chemotherapy,
- recurrence

FullText(HTML)

References (17)

References

[1]	LHEUREUX S, GOURLEY C, VERGOTE I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177): 1240-1253. doi: 10.1016/S0140-6736(18)32552-2
[2]	陈雨莲, 史庭燕, 臧荣余. 铂敏感复发卵巢癌手术相关问题与规范化诊疗[J]. 中国实用妇科与产科杂志, 2021, 37(6): 616-619. doi: 10.19538/j.fk2021060105
[3]	XIANG L, KONG B H. PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas[J]. Oncol Lett, 2013, 5(3): 735-738. doi: 10.3892/ol.2013.1121
[4]	DI PALMA T, LUCCI V, DE CRISTOFARO T, et al. A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells[J]. BMC Cancer, 2014, 14: 292. doi: 10.1186/1471-2407-14-292
[5]	BATTAGLIA R A, DELIC S, HERRMANN H, et al. Vimentin on the move: new developments in cell migration[J]. F1000Res, 2018, 7: F1000FacultyRev-F1000Faculty1796.
[6]	王秋宇, 李晓翔, 朱军义. 上皮性卵巢癌初次肿瘤细胞减灭术后复发情况及影响因素分析[J]. 现代肿瘤医学, 2019, 27(2): 307-310. doi: 10.3969/j.issn.1672-4992.2019.02.032
[7]	LEUNG S O A, KONSTANTINOPOULOS P A. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies[J]. Expert Opin Investig Drugs, 2021, 30(7): 695-707. doi: 10.1080/13543784.2021.1939305
[8]	POVEDA A, FLOQUET A, LEDERMANN J A, et al. Olaparib Tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(5): 620-631. doi: 10.1016/S1470-2045(21)00073-5
[9]	EL BAIRI K, AL JARROUDI O, AFQIR S. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer[J]. Semin Cancer Biol, 2021, 77: 42-55. doi: 10.1016/j.semcancer.2021.03.031
[10]	MURATOVSKA A, ZHOU C M, HE S J, et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival[J]. Oncogene, 2003, 22(39): 7989-7997. doi: 10.1038/sj.onc.1206766
[11]	BOWEN N J, LOGANI S, DICKERSON E B, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development[J]. Gynecol Oncol, 2007, 104(2): 331-337. doi: 10.1016/j.ygyno.2006.08.052
[12]	TACHA D, ZHOU D, CHENG L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study[J]. Appl Immunohistochem Mol Morphol, 2011, 19(4): 293-299. doi: 10.1097/PAI.0b013e3182025f66
[13]	RODGERS L H, Ó HAINMHIRE, YOUNG A N, et al. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium[J]. Oncotarget, 2016, 7(22): 32785-32795. doi: 10.18632/oncotarget.9051
[14]	GHANNAM-SHAHBARI D, JACOB E, KAKUN R R, et al. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma[J]. Oncogene, 2018, 37(17): 2213-2224. doi: 10.1038/s41388-017-0040-z
[15]	HUO Y, ZHENG Z G, CHEN Y L, et al. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells[J]. Oncotarget, 2016, 7(29): 45876-45888. doi: 10.18632/oncotarget.9970
[16]	杨东, 杨宇, 白云波, 等. 卵巢癌组织ERCC1、波形蛋白表达与临床病理特征及预后的关系分析[J]. 现代生物医学进展, 2020, 20(5): 862-865, 909.
[17]	SATELLI A, LI S L. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci, 2011, 68(18): 3033-3046.

Cited By

Get Citation

PDF

XML

Article views (169) PDF downloads (20)

Turn off MathJax

Article Contents

Abstract

References

Correlations of expression of paired-box gene family 8 and vimentin in epithelial ovarian cancer tissue with clinicopathologic features and recurrence after chemotherapy

Abstract

References

Catalog

Export File

Citation

Format

Content